Eli Lilly Signs $5.9 Billion Oncology Licensing Agreement with Stipple Bio
Eli Lilly (LLY) has entered into an exclusive global licensing agreement with Cambridge-based biotech firm Stipple Bio to collaborate on the discovery and commercialization of new cancer treatments. The strategic partnership is structured as a multi-target, multi-modality initiative aimed at expanding Lilly's oncology pipeline. The deal is valued at up to $5.9 billion, which includes potential milestone payments. This collaboration underscores Eli Lilly's ongoing commitment to investing in advanced biotechnology to secure long-term growth in the high-value oncology sector.

Tickers: $LLY
Topics: biotechnology drug discovery licensing deal pharmaceuticals
Read the full article at Seeking Alpha
Part of the story Eli Lilly to Acquire Calytrix Bio in Deal Valued Up to $1.5 Billion (2 articles)